Impact of adjuvant chemoradiation on survival in patients with resectable cholangiocarcinoma

Dover, Laura; Oster, Robert A.; McDonald, Andrew M.; DuBay, Derek A.; Wang, Thomas J.; Jacob, Rojymon

doi:10.1016/j.hpb.2016.07.008

Cited by 15 publications

(22 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies related lymph-node status (regional lymph nodes metastases) to poor survival. [6,7,13,18] The same result was seen in this study ( P = .032). Our study also found a relationship between liver reduction rate >30% and treatment outcome ( P = .016).…”

Section: Discussionsupporting

confidence: 88%

See 1 more Smart Citation

Outcome of postoperative radiation therapy for cholangiocarcinoma and analysis of dose-volume histogram of remnant liver

Mukai¹,

Matsuyama

Koike³

et al. 2019

Medicine

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 88%

“…In the present study, MST was 40 months, 2-year OS was 72.4%, and LC was 65.3%. The 40-month MST was similar to, or longer than, that in previous studies (13–37 months) [6,7,12,13,18–21] ; OS was also similar to previous studies. [6,22–24] A few reports clearly address in-field recurrence.…”

Section: Discussionsupporting

confidence: 88%

Outcome of postoperative radiation therapy for cholangiocarcinoma and analysis of dose-volume histogram of remnant liver

Mukai¹,

Matsuyama

Koike³

et al. 2019

Medicine

View full text Add to dashboard Cite

show abstract

“…However, in three of the studies, the margin status was R0 or R1, and R0 accounted for the majority of patients. The 2year OS and MST rates of patients who receive adjuvant chemoradiotherapy or radiation therapy range from 57.9-60% and 30.2-36.9 months, respectively [4,26,27,28,29]. In these reports, only R0 or R1 patients were included, and the median radiation doses ranged from 45-59.4 Gy, and 28-100% of patients received concurrent chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Makers Including Immune and Inflammatory Factors Predict Outcomes in Patients Receiving Postoperative Radiation Therapy for Cholangiocarcinoma

Mukai

Matsuyama

Sugiura

et al. 2020

Preprint

View full text Add to dashboard Cite

Purpose: This study aimed to analyze treatment outcomes and prognostic markers, including immune and inflammatory factors, of postoperative radiation therapy (RT) administered to patients with cholangiocarcinoma (CCA).Methods: We retrospectively selected 59 patients with CCA who underwent surgery and postoperative RT with curative intent from 2004 to 2019. Patients received external irradiation (50 Gy in 25 fractions) using three-dimensional RT. Overall survival (OS), cause-specific survival (CSS), progression-free survival (PFS), and locoregional control (LRC) rates of initial RT were assessed using the Kaplan–Meier method. Univariate and multivariate Cox proportional-hazards regression models were used to identify prognostic factors. We analyzed prognostic factors of inflammation, such as pre-RT platelet count, hemoglobin, lymphocyte count ratio (LCR) of the leukocyte count, platelet-to-lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio (NLR).Results: Tumor stages were distributed as follows: I (n = 8), II (n = 25), III (n = 15), and IVA (n = 11). The median follow-up was 24 months. Two-year OS, CSS, PFS, and LRC rates were 59.5%, 62.0%, 40.1%, and 66.7%, respectively. Univariate analysis revealed that lower LCR was significantly associated with shorter PFS (P = 0.0446, hazard ratio (HR): 1.90, 95%, confidence interval (CI): 1.02–3.58). There was no significant difference between the median baseline values of PLR and NLR; and age ≥75, positive regional lymph node metastases (N+), and chemotherapy after RT were significantly associated with poor OS. Multivariate analysis revealed a significant association of N+ with OS, PFS and CSS and that lower LCR was significantly associated with PFS (HR: 0.481, CI: 0.252–0.905, p=0.0234). Among late toxicity events, two patients (3.38%) were suspected with therapy-related liver toxicity.Conclusions: LCR before RT was a prognostic factor for postoperative radiation therapy of patients with CCA.

show abstract

“…However, the sensitivity of these tests in the diagnosis of CCA is limited, especially in the early stages of the disease [ 25 ]. Management strategies include multispecialty treatments, with consideration of surgical resection, targeted radiation therapy, and systemic chemotherapy [ 24 , 26 , 27 ]. Surgical resection is the only potentially curative treatment, but the majority of patients present with advanced cancer and recurrence after resection is common [ 16 ].…”

Section: Epidemiology Risk Factors Diagnosis and Treatment Of Ccamentioning

confidence: 99%

The role of extracellular vesicles in cholangiocarcinoma

Bai

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) is a rare tumor that arises from cholangiocytes, the epithelial cells of the bile duct. The tumor is characterized by insidious onset, high degree of malignancy, poor prognosis and high recurrence rate. Due to the lack of specific biomarkers, it is difficult to diagnose CCA early and evaluate prognosis. Extracellular vesicles (EVs), which include apoptotic bodies, microvesicles and exosomes, have emerged as having important roles in cellto-cell communication in both normal physiology and pathological conditions. Some research has found that EVs play a crucial role in the occurrence and development of CCA. EVs can carry specific molecular substances such as nucleic acids and proteins, which have potential for the diagnosis and therapy of CCA. This article reviews the current knowledge on the role of EVs in CCA. We highlight EVs and their functions in the physiology and pathophysiology of CCA, and discuss their therapeutic potential and their role as biomarkers.

show abstract

Impact of adjuvant chemoradiation on survival in patients with resectable cholangiocarcinoma

Abstract: Background: The ideal adjuvant therapy for resected cholangiocarcinoma remains controversial. Na-

Cited by 15 publications

References 26 publications

Outcome of postoperative radiation therapy for cholangiocarcinoma and analysis of dose-volume histogram of remnant liver

Outcome of postoperative radiation therapy for cholangiocarcinoma and analysis of dose-volume histogram of remnant liver

Prognostic Makers Including Immune and Inflammatory Factors Predict Outcomes in Patients Receiving Postoperative Radiation Therapy for Cholangiocarcinoma

The role of extracellular vesicles in cholangiocarcinoma

Contact Info

Product

Resources

About